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ABSTRACT 
Mental retardation is a frequent condition that is clinically and genetically highly 
heterogeneous. One of the strategies used to identify new causative genes is to take 
advantage of balanced chromosomal rearrangements in affected patients. We 
characterized a de novo t(10;13) balanced translocation in a patient with severe mental 
retardation and major hypotonia. We found that the balanced translocation is 
molecularly balanced. The translocation breakpoint disrupts the coding sequence of a 
single gene, called ATP8A2. The ATP8A2 gene is not ubiquitously expressed but it is 
highly expressed in the brain. In situ hybridization performed in mouse embryos at 
different stages of development with the mouse homologue confirms this observation. 
38 patients with a similar phenotype were screened for mutations in the ATP8A2 gene 
but no mutations were found. The balanced translocation identified in this patient 
disrupts a single candidate gene highly expressed in the brain. Although this 
chromosomal rearrangement could be the cause of the severe phenotype of the patient, 
we were not able to identify additional cases. Extensive screening in the mentally 
retarded population will be needed to determine if ATP8A2 haploinsufficiency or 
dysfunction causes a neurological phenotype in humans. 
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INTRODUCTION 
Mental retardation is a frequent condition that is clinically and genetically highly 
heterogeneous (1). Mutations in hundreds of different genes have been identified in 
patients suffering from mental retardation and these genes encode proteins performing a 
wide range of molecular functions inside and outside the central nervous system (2). 
Despite its important prevalence, ranging between 0,5 and 3% of the population, the 
majority of mental retardation cases remain unexplained. 
The presence of de novo chromosomal rearrangements in patients with an abnormal 
phenotype can be used to identify disease-causing genes (3). Cloning of the breakpoints 
of balanced chromosomal translocations in affected patients has led to the identification 
of a large number of genes, including genes implicated in different types of mental 
retardation phenotypes (4). 
Here, we describe a female patient with moderate mental retardation, severe hypotonia, 
and a de novo balanced translocation 46,XX,t(10;13)(p12.1;q12.13)dn. We cloned and 
sequenced the two translocation breakpoints and showed that the translocation is 
perfectly balanced at the molecular level. Analysis of the breakpoint regions reveals that 
the coding sequence of a P-type ATPase called ATP8A2 on chromosome 13q12.13 is 
interrupted by the translocation whereas there is no known transcription unit located in 
the immediate vicinity of the chromosome 10 breakpoint. We analyzed the expression 
pattern of the ATP8A2 transcript in mice using in situ hybridization and in human using 
RT-PCR. We show that ATP8A2 is highly expressed in the brain and testis both in 
human and mouse. We hypothesize that haploinsufficiency of the ATP8A2 gene could 
be involved in the severe neurological phenotype presented by the patient with the 
balanced translocation. 
MATERIALS AND METHODS 
Cell lines, karyotyping, FISH and array CGH 
Karyotypes were determined by analysis of R-banded chromosomes at a minimum 
resolution of 550 bands using standard protocols. FISH was performed on metaphase 
chromosomes of the patient using BAC clones DNA (provided by the Wellcome Trust 
Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK) and commercial probe 
CEP10 (Abbott Molecular Laboratories, USA). Hybridization was performed using the 
standard procedures. Array-CGH was performed using the Agilent Human Genome 
244K CGH Microarray (Agilent Technologies, Inc., Santa Clara, CA). The microarray 
chip was scanned on an Agilent Microarray Scanner. Data were processed by Agilent 
Feature Extraction software 9.5 and analyzed with Agilent CGH Analytics 3.4 
Software. 
RNA extraction,  reverse transcription and PCR 
Total RNA was extracted using TRIzol reagent (Invitrogen Corp., Carlsbad, CA). 
Reverse transcription of 5 μg of total RNA was performed in 20 μl of Superscript 
reaction buffer (Invitrogen Corp., Carlsbad, CA) containing 0.01M dithiothreitol (DTT), 
7.5 ng/μl of dN6, 40 U of Rnase inhibitor (Invitrogen Corp., Carlsbad, CA), 0,5 mM 
dNTP and 200 U of Superscript reverse transcriptase (Invitrogen Corp., Carlsbad, CA). 
Real-time PCR reactions were performed in the LightCycler 480 system (Roche) using 
the SYBR Green I Master Kit (Eurogentec, Seraing, Belgium) with 2 μl of cDNA and 
200 nM of each primer. Each reaction was performed in triplicate. 
In situ hybridization on mouse embryos 
The antisense and sense riboprobes used in this study correspond to nucleotides 2943-
3637 of sequence NM_015803 (mouse Atp8a2). In situ hybridization was performed as 
previously described (5). Control experiments were performed using corresponding 
sense riboprobes on adjacent sections, giving either no signal or a uniformly low 
background as expected. 
 
RESULTS 
Case report 
The patient is the first child of non consanguineous, healthy parents. During pregnancy, 
the mother was given Zovirax for 5 days because she had been in contact with a patient 
suffering from chicken pox. The patient was born at term and with normal growth 
parameters (height 50cm, weight 3180g, OFC 36cm). The first clinical signs were noted 
after one month when she was noticed not to be able to hold her head. CT-scan, muscle 
enzymes, amino acids, organic acids and thyroid hormones were normal in the blood of 
the patient. At one year of age she had major axial hypotonia. She was not able to hold 
her head and could not sit. She was demonstrating incessant abnormal movements. She 
had a normal EEG. Nerve conduction velocity and electromyogram were normal, as 
were her visual and hearing parameters. The brain MRI performed at 13 months of age 
was reported to be normal. At three years of age, she had normal growth parameters but 
was still severely hypotonic and was not able to hold her head. She could speak a few 
words.  
 
Cytogenetic and molecular characterization of the translocation 
The routine karyotype revealed a translocation between chromosomes 10p12 and 13q12 
(data not shown). Serial FISH experiments lead to the identification of two BAC clones 
overlapping the translocation breakpoints (supplementary figure S1). BAC clone RP11-
164A7 overlaps the chromosome 10 breakpoint at 10p12.1. BAC clones RP11-111G7 
and RP11-467D10 overlap the chromosome 13 breakpoint at 13q12.13. A map of the 
translocation breakpoint regions on chromosomes 10 and 13 is presented in Figure 1. 
Array comparative genomic hybridization (a-CGH) was performed using an Agilent 
244K CGH array and did not reveal any genomic imbalance at the resolution level 
provided by the array (data not shown).  
To further refine the localization of the translocation breakpoints, Southern blots were 
prepared using the patient's DNA. Series of probes were prepared using PCR on the 
chromosome 13 breakpoint overlapping BAC DNA and the Southern blots were 
hybridized with these probes until a junction fragment could be identified. A 4.8 kb 
junction fragment was identified on the patient's DNA using the StuI restriction 
endonuclease and a probe located at position 70508-70999 on the RP11-164A7 BAC 
DNA sequence (supplementary figure S2). This junction fragment was cloned and 
sequenced (supplementary document S3). Analysis of the sequence of this fragment 
allowed us to map the chromosome 10 breakpoint at position 28,846,023 bp and the 
chromosome 13 breakpoint at position 25,231,633 bp (according to reference sequence 
Ensembl54) and to show that the translocation is perfectly balanced with no gain or loss 
of genomic material. 
The chromosome 10 breakpoint does not interrupt a known transcription unit. A gene 
called WAC (WW domain containing adaptor with coiled-coil) is located 15,7 kb 
towards the centromere of chromosome 10. A gene called MPP7 is located 235 kb away 
on the telomeric side of the chromosome 10 breakpoint. The chromosome 13 breakpoint 
is located between exons 27 and 28 of a gene called ATP8A2, recently shown to encode 
a putative phosphatidylserine flippase (6). In order to test if a chimaeric transcript could 2 
be produced between ATP8A2 and MPP7 on the der(13), we used primers located in 
ATP8A2 (exon 24) and MPP7 (exon 10) and tried to amplify a chimaeric transcript 
using cDNA prepared from RNA extracted from the lymphocytes of the patient. We 
were not able to detect any chimaeric transcript. 
 
 
Expression of ATP8A2 in human and mouse tissues 
In order to study the expression profile of ATP8A2, we performed RT-PCR on a panel 
of 13 human tissues. ATP8A2 was found to be highly expressed in testis and brain 
(Figure 2A). To refine the brain expression profile, we next used a panel of RNAs 
prepared from 12 human brain areas to perform RT-PCR. This experiment revealed that 
ATP8A2 is expressed similarly in the different brain regions tested. 
The human ATP8A2 and mouse Atp8a2 proteins share 97% homology. We thus 
performed in situ hybridization in the mouse with a murine Atp8a2 antisense probe. 
These experiments were performed in E14.5, E15.5, E18.5 embryos and at postnatal day 
3 (P3). We observed a strong and homogeneous brain expression at all studied stages 
with the highest levels of Atp8a2 transcripts detected before birth (Figure 2B). 
Because ATP8A2 is not expressed in lymphocytes, we were not able to quantify its 
expression in the cells of the patient. The expression of MPP7 could not be tested either 
because it is not expressed in the lymphocytes (data not shown). We could quantify the 
expression of WAC in the lymphocytes of the patients, her two parents and a control cell 
line using real-time quantitative PCR. We found no difference in the amount of WAC 
transcript in the four samples tested (data not shown).  
 
Screening of the ATP8A2 gene for mutations 
We sequenced the 37 exons of the ATP8A2 allele located on the normal chromosome 13 
in the patient with the balanced translocation but found no mutation. We also sequenced 
all ATP8A2 exons on 38 additional patients selected because they were suffering both 
from mental retardation and severe hypotonia. Again, we found no deleterious mutation 
(data not shown). This group of patient had been investigated using 105K array CGH 
and no gross rearrangement was found (31 oligonucleotides cover the ATP8A2 gene on 
these arrays). 
 
DISCUSSION 
We have studied a patient with mental retardation, severe hypotonia and a de novo 
balanced translocation. We have cloned and sequenced the two translocation 
breakpoints and we have shown that the translocation is molecularly balanced. Based on 
the results obtained, we find it reasonable to hypothesize that the breakpoint on 
chromosome 10 is not involved in the phenotype of our patient. This hypothesis is 
based on the fact that this region of the genome does not contain any gene. The closest 
gene to the breakpoint on chromosome 10 is the WAC gene, located 15,7 kb away 
towards the centromere. The function of the protein encoded by the WAC gene is 
unknown. We have shown that the expression of WAC is not altered in the patient's 
lymphoblastoid cell line, ruling out a major position effect, although the expression in 
the brain of the patient is unknown. 
If the phenotype of the patient is caused by the presence of the translocation, then we 
propose that it is due to the haploinsufficiency of the ATP8A2 gene on chromosome 13. 
A possibility exists that a chimaeric transcript could be produced using ATP8A2 exons 1 3 
4 
to 27 and the MPP7 exons, in the brain. In this later case however, ATP8A2 dosage 
would also be altered. The interruption of the coding region of the gene by the 
translocation breakpoint is a strong argument in favour of the pathogenicity of the 
chromosomal rearrangement. Expression analysis in mouse and human shows that 
ATP8A2 is strongly expressed in the brain and during development. Several studies 
have addressed the function of the ATP8A2 gene. Injection of an antisense ATP8A2 
cDNA construct was shown to cause a loss of growth control and to convert non 
tumorigenic AIG cells into tumorigenic cells (7). A study of the mouse Atp8a2 gene 
revealed that it was highly expressed in the central nervous system and that it could 
transport aminophospholipids (8). More recently, ATP8A2 was confirmed to be 
involved in the energy-dependent translocation of phosphatidylserine across the cell 
membrane of photoreceptors (6). Phosphatidylserine plays important roles in several 
biological processes including apoptosis or cell signalling. Alteration of 
phosphatidylserine receptor (PSR) in the mouse reveals that it is necessary for proper 
brain development (9). 
Terminal deletions of chromosome 13 are rare but they represent a well known clinical 
entity (10). Deletions of 13q14 have extensively been studied in the context of 
retinoblastoma (11). On the contrary, proximal deletions affecting the 13q12 region 
have not been frequently reported. An interstitial 13q12.1q14.1 deletion was reported in 
a patient with developmental delay, dysmorphic features and hypotonia (12). The 
rearrangement was inherited from a normal mother with a complex chromosomal 
rearrangement. This later case was not characterized molecularly and it is not known if 
the ATP8A2 gene was involved. Deletions in the 13q13-q31 region cause growth 
retardation but are usually not associated with major malformations (13). 
The screening of additional patients revealed no mutations in the ATP8A2 gene. 
However, it is very difficult to select patients for mutation screening because the 
phenotype of the patient carrying the balanced translocation is not very specific, 
although severe. Mental retardation and severe hypotonia are found in several other 
syndromes such as Prader-Willi patients when they are young. However, in many 
instances, the clinical course of these disorders when the patients grow older usually 
reveals additional features. Given that our patient is still rather young, we were not able 
to refine the clinical diagnosis enough to select a clinically matched patient cohort for 
molecular screening. 
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TITLES AND LEGENDS TO FIGURES 
 
Figure 1 
Top panel : ideograms of human chromosomes 10 (Hs.10) and 13 (Hs.13). Middle panel 
: BAC clones and gene content in the two regions investigated by FISH and Southern 
blotting. Arrows indicate the direction of transcription for each gene in the region. The 
size of each gene and the number of exons are also indicated. Bottom panel : position of 
the two translocation breakpoints with respect to the exons of the WAC and ATP8A2 
genes (large white arrows). The location and number of exons contained in the 
breakpoint region is indicated for each gene (exons 1 to 3 for the WAC gene, exons 26 
to 28 for the ATP8A2 gene). The chromosome 10 breakpoint is located at nucleotide 
28,846,023 and the chromosome 13 breakpoint at position 25,231,633 (according to 
reference sequence Ensembl54). 
 
Figure 2 
A. Expression of ATP8A2 (top panels) and GAPDH (bottom panels) in 13 human 
tissues (left panels) and in 12 regions of the human brain (right panels). ATP8A2 is 
strongly expressed in all regions of the brain, in the retina and testis. A faint signal is 
also detected in the foetal kidney. B. In situ hybridization performed with a mouse 
Atp8a2 probe on sections of embryos at E14.5 (a-c), E15.5 (d-e) and E18.5 (g-h). 
Atp8a2 is strongly expressed in the central nervous system. A faint background staining 
only is visible on the sections hybridized with an Atp8a2 sense probe (f and i). C. In situ 
hybridization performed on postnatal day 3 (P3) and day 10 (P10) mouse brain 
1 
revealing a strong expression of Atp8a2 in the cerebral cortex and the hippocampus. 
Sections hybridized with an Atp8a2 sense probe are shown (b and d). 
SUPPLEMENTARY FIGURES AND DOCUMENTS 
 
Figure S1. 
Fluorescent in situ hybridization performed on the patient's metaphase chromosome 
with BAC clones overlapping with the translocation breakpoint : RP11-164A7 on 
chromosome 10 (A), RP11-111G7 (B) and RP11-467D10 (C) on chromosome 13. BAC 
clones are labelled with a Cy5 (red). A chromosome 10 centromeric probe (CEP10) was 
co-hybridized and labelled with Cy3 (green). 
 
Figure S2. 
Southern blot prepared using the DNA of the patient and her father digested by the StuI 
restriction endonuclease. A 4.8 kilobases abnormal restriction fragment (arrow) is 
detected in the patient's DNA only. 
 
Supplementary document S3. 
Sequence of the 4864 bp StuI junction fragment. 


